Pembimbing :
dr. Catharina Rini Pratiwi, Sp. A
Penulis:
William O. Cooper, M.D., M.P.H., Laurel A. Habel, Ph.D., Colin M. Sox, M.D., K. Arnold
Chan, M.D., Sc.D., Patrick G. Arbogast, Ph.D., T. Craig Cheetham, Pharm.D., Katherine T.
Murray, M.D., Virginia P. Quinn, Ph.D., M.P.H., C. Michael Stein, M.B., Ch.B., S. Todd
Callahan, M.D., M.P.H., Bruce H. Fireman, M.A., Frank A. Fish, M.D., Howard S. Kirshner,
M.D., Anne O’Duffy, M.D., Frederick A. Connell, M.D., M.P.H., and Wayne A. Ray, Ph.D.
Tanggal Terbit:
1 November 2011
Dipublikasikan oleh:
Massachusetts Medical Society
Obat-obatan yang digunakan untuk mengobati attention
deficit-hyperactivity disorder (ADHD) diresepkan untuk lebih
dari 2,7 juta anak di Amerika Serikat setiap tahunnya dan
telah dianggap relatif aman.
dexmethylphenidate, dextroamphetamines,
amphetamine salts, atomoxetine, or pemoline)
• C = Kontrol (Bukan Pengguna)
• O = Kejadian penyakit Cardiovaskular serius (infark
miocard, gagal jantung, kematian jantung)
Tittle and Authors
No Criterias
1 Number of words in title <12 words (+)
2 Title description Describes the main
content of the study
3 The author list corresponds to the (+)
journal
4 The author's correspondence (+)
5 Place and time of research in the (-)
title
Abstract
No Criterias
1 Abstract consists 4 paragraph: (+)
-Background
-Methods
-Results
-Conclusion
2 Informative (+)
3 Include keywords (+)
4 Less than 250 words (-) 336 words
Introduction
No Criterias Yes (+), No (-)
No Criterias
1 Number of subjects (+)
2 Table of subject characteristics (+)
3 Table of research results (+)
4 Comments and opinions about the (+)
results of the author
Disscusion, Conclusion, and Reference
No Criterias
1 Discussion and conclusion are separate (-)
2 Discussions and conclusions are (+)
presented clearly
3 The discussion refers to previous (+)
research
4 The discussion fits the theoretical basis (+)
5 Main conclusion (+)
6 Conclusions based on research (+)
7 Research suggestions (+)
8 Writing the bibliography according to (+)
the rules
VALIDITY
Questions Answers
Is the patient's allocation in this study No
randomized?
Is the patient's observation long Yes
enough and complete?
Are all patients in the group No
randomized, analyzed?
Are patients and doctors still blind in No
doing therapy, apart from the therapy
being tested?
Are the therapy and control groups the No
same?
APPLICABLE
Questions Answers
Are there any differences in our Yes
patients compared to those in previous
studies?
Is it possible to apply to our patients? Yes
Does the patient have a potentially PROFITABLE
beneficial or adverse potential when
the therapy is applied?